Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | LPL | P06858 | 3/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24484115 | 0.78 | NPC1 (0.38) | KDM4E | |
| SCHEMBL31752895 | 0.71 | CA2 (0.38) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL24469892 | 0.71 | CA2 (0.38) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL16515618 | 0.68 | SMN1; SMN2 (0.47) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL24469863 | 0.66 | CA2 (0.43) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL31398250 | 0.65 | CA2 (0.42) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL15330247 | 0.65 | HDAC4 (0.44) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL24469820 | 0.65 | CA2 (0.42) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL12260592 | 0.64 | ALDH1A1 (0.65) | CA2CA1KDM4ETSHR | |
| SCHEMBL16745628 | 0.63 | NR1H2 (0.43) | CA2LPLLIPGCA1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | CA2 945/4885LPL 1210/4885LIPG 1675/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | CA2 945/4885LPL 1210/4885LIPG 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.